Darzalex clinical trials
Darzalex is named as an intervention in 23 current clinical trials in our USA, France, China, UK, Germany, Spain, Canada, Japan, South Korea, Italy, Australia, Israel, Poland, Brazil, Taiwan, Netherlands, Norway, Turkey, Belgium, Sweden, Austria, Czechia, Mexico, India and Egypt registers. 13 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Regeneron Pharmaceuticals (3). The most-studied condition is Multiple Myeloma.
Patient leaflets for Darzalex
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Darzalex
23 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Darzalex
32 conditionsAll 32 conditions
| Condition (as registered) | Trials |
|---|---|
| Multiple Myeloma | 12 |
| High Risk Smoldering Multiple Myeloma (HR-SMM) | 1 |
| Relapsed Refractory Multiple Myeloma | 1 |
| Relapsed and/or Refractory Multiple Myeloma (RRMM) | 1 |
| NHL | 1 |
| Blood Cancer | 1 |
| Refractory Non-Hodgkin Lymphoma | 1 |
| Myeloma Multiple | 1 |
| Kahler Disease | 1 |
| Myeloma, Plasma Cell | 1 |
| T Acute Lymphoblastic Leukemia | 1 |
| Neuromyelitis Optica | 1 |
| Neuromyelitis Optica Spectrum Disorder | 1 |
| NMO Spectrum Disorder | 1 |
| Primary Plasma Cell Leukemia | 1 |
| Extramedullary Multiple Myeloma | 1 |
| Newly Diagnosed Multiple Myeloma | 1 |
| Newly Diagnosed | 1 |
| High Risk | 1 |
| MRD | 1 |
| Toxic Epidermal Necrolysis | 1 |
| Immunotherapy | 1 |
| Cutaneous Adverse Drug Reactions (CADR) | 1 |
| Adult Patients With Adverse Risk Acute Myeloblastic Leukemia | 1 |
| Multiple Myeloma, Newly Diagnosed | 1 |
| Deletion 17P Syndrome | 1 |
| Monoclonal Gammopathy | 1 |
| Smoldering Multiple Myeloma | 1 |
| Refractory Multiple Myeloma | 1 |
| Multiple Myeloma in Relapse | 1 |
| Relapse | 1 |
| Smoldering Plasma Cell Myeloma | 1 |
Sponsors
lead sponsor per trial+ 6 more sponsors in the trial list above.
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Darzalex trials
How many clinical trials are testing Darzalex?
23 current trials in our USA, France, China, UK, Germany, Spain, Canada, Japan, South Korea, Italy, Australia, Israel, Poland, Brazil, Taiwan, Netherlands, Norway, Turkey, Belgium, Sweden, Austria, Czechia, Mexico, India and Egypt registers name Darzalex as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Darzalex trials recruiting patients?
Yes. 13 of the 23 trials are recruiting: 7 with sites in USA, 6 with sites in France, 4 with sites in China, 4 with sites in UK, 2 with sites in Germany, 3 with sites in Spain, 3 with sites in Canada, 3 with sites in Japan, 4 with sites in South Korea, 2 with sites in Italy, 3 with sites in Australia, 1 with sites in Israel, 3 with sites in Poland, 3 with sites in Brazil, 3 with sites in Taiwan, 1 with sites in Netherlands, 2 with sites in Norway, 2 with sites in Turkey, 2 with sites in Belgium, 1 with sites in Sweden, 1 with sites in Austria, 1 with sites in Czechia, 1 with sites in Mexico, 1 with sites in India and 1 with sites in Egypt. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Darzalex clinical trials?
Regeneron Pharmaceuticals (3), AstraZeneca (1), Celgene (1) and Pfizer (1), among 21 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Darzalex works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Darzalex works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Darzalex (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.